newsfilter
← Latest News
GlobeNewswire·

Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204

Data Safety Monitoring Committee approves advancing to a higher dose of 90mCi The first two Cohorts' patients show tumor uptake and a favourable safety profile SYDNEY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Radiopharm